GSK Plc agreed to buy an experimental medicine to treat liver disease for as much as $2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker ...

A high yield can be attractive, but the most critical factor to consider is a company's underlying operations. Here are two ...

Disc Medicine, Inc. announced significant advancements ... efforts for bitopertin as well as development of the rest of our pipeline. We expect data from ongoing trials of DISC-0974, the Phase ...

In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and ...

"This quarter we continued to advance our promising neurology genomic medicine pipeline and are pleased to have signed our third STAC-BBB license agreement, reinforcing that Sangamo is a ...

Strategic priorities did not shift markedly, with primary attention on INO-3107's advancement and the next-generation DNA medicine platform. Management acknowledged the evolving nature of tariffs ...